Literature DB >> 8137849

Prognosis after extracorporeal shock wave lithotripsy of radiopaque renal calculi: a multivariate analysis.

D K Ackermann1, R Fuhrimann, D Pfluger, U E Studer, E J Zingg.   

Abstract

To obtain a better understanding of the prognostic factors influencing treatment outcome after extracorporeal shock wave lithotripsy (ESWL), a multivariate logistic analysis of the data from 246 patients has been undertaken. All of the patients were treated with the Dornier lithotriptor HM-3 for radiopaque renal calculi. Treatment success was defined as stone-free within 3 months of one ESWL session and without adjuvant measures after ESWL. In a first analysis, 210 patients with solitary and multiple calculi without adjuvant measures before ESWL were studied. Of 210 patients, 141 (67%) were free from stones after 3 months). Significant influences on the success rate were body mass index and stone number. In a second analysis only those 160 patients with solitary calculi were considered. In this group, age, body mass index, stone location, stone burden and serum calcium significantly influenced the prognosis. When patients with adjuvant measures were added to the analysis an increasing prognostic importance of the stone burden was seen. In patients with a small to medium stone burden (< 4.0 cm3), the number of stones seemed to be more important than the stone burden. Patients appear to have the best chance for successful ESWL when their body mass index is between 20 and 28, their age is between 40 and 60 years, their stones are in the renal pelvis and solitary, the stone burden is < 1.0 cm3, and when their serum calcium is normal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137849     DOI: 10.1159/000475261

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

Review 1.  [Controversy on lower pole stones: monitor or intervene?].

Authors:  A Häcker; M S Michel
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  Age-related delay in urinary stone clearance in elderly patients with solitary proximal ureteral calculi treated by extracorporeal shock wave lithotripsy.

Authors:  Osamu Ichiyanagi; Akira Nagaoka; Takuji Izumi; Yuko Kawamura; Tomoyuki Kato
Journal:  Urolithiasis       Date:  2015-05-16       Impact factor: 3.436

Review 3.  Recent advances in lithotripsy technology and treatment strategies: A systematic review update.

Authors:  H E Elmansy; J E Lingeman
Journal:  Int J Surg       Date:  2016-11-24       Impact factor: 6.071

4.  Prognostic factors of success of extracorporeal shock wave lithotripsy (ESWL) in the treatment of renal stones.

Authors:  Abdulla Al-Ansari; Khalid As-Sadiq; Sami Al-Said; Nagy Younis; Osama A Jaleel; Ahmed A Shokeir
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  Obesity might not be a disadvantage for SWL treatment in children with renal stone.

Authors:  Oktay Akça; Rahim Horuz; Mustafa Yücel Boz; Alper Kafkasli; Okan Gökhan; Cemal Göktaş; Kemal Sarica
Journal:  Int Urol Nephrol       Date:  2013-01-09       Impact factor: 2.370

6.  Is shock wave lithotripsy efficient for the elderly stone formers? Results of a matched-pair analysis.

Authors:  Prodromos Philippou; Djelali Lamrani; Konstantinos Moraitis; Christian Bach; Junaid Masood; Noor Buchholz
Journal:  Urol Res       Date:  2011-09-08

Review 7.  Ureteroscopy for the management of stone disease.

Authors:  Brian H Eisner; Michael P Kurtz; Stephen P Dretler
Journal:  Nat Rev Urol       Date:  2009-12-01       Impact factor: 14.432

8.  Optimizing shock wave lithotripsy: a comprehensive review.

Authors:  Paul D McClain; Jessica N Lange; Dean G Assimos
Journal:  Rev Urol       Date:  2013

9.  Pediatric extracorporeal shock wave lithotripsy: Predicting successful outcomes.

Authors:  Sean McAdams; Aseem R Shukla
Journal:  Indian J Urol       Date:  2010-10

10.  Management of 1-2 cm renal stones.

Authors:  Aneesh Srivastava; Saurabh S Chipde
Journal:  Indian J Urol       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.